1. Research advances and treatment perspectives of pancreatic adenosquamous carcinoma

   • Wen Zhang
   • Jing Zhang
   • Jin Ding

   Review 01 November 2022 Pages: 1 - 15

   

2. Immunosuppression, immune escape, and immunotherapy in pancreatic cancer: focused on the tumor microenvironment

   • Yu-Heng Zhu
   • Jia-Hao Zheng
   • Yan-Miao Huo

   Review 11 November 2022 Pages: 17 - 48

   

3. In vivo study revealed pro-tumorigenic effect of CMTM3 in hepatocellular carcinoma involving the regulation of peroxisome proliferator-activated receptor gamma (PPARγ)

   • Jiahui Wang
   • Hongjin Chu
   • Fujun Liu

   Original Article 26 October 2022 Pages: 49 - 64

   

4. CoQ₁₀ reduces glioblastoma growth and infiltration through proteome remodeling and inhibition of angiogenesis and inflammation

   • Javier Frontiñán-Rubio
   • Emilio Llanos-González
   • Mario Durán-Prado

   Original Article Open access 02 November 2022 Pages: 65 - 77

   

5. FUT8 is regulated by miR‐122‐5p and promotes malignancies in intrahepatic cholangiocarcinoma via PI3K/AKT signaling

   • Fanghua Chen
   • Yin Li
   • Shu Zhang

   Original article 08 November 2022 Pages: 79 - 91

   

6. AKT-driven epithelial-mesenchymal transition is affected by copper bioavailability in HER2 negative breast cancer cells via a LOXL2-independent mechanism

   • Alessandra Vitaliti
   • Ilenia Roccatani
   • Luisa Rossi

   Original Article Open access 01 December 2022 Pages: 93 - 115

   

7. Dual anti-angiogenic and anti-metastatic activity of myriocin synergistically enhances the anti-tumor activity of cisplatin

   • Ji-Hak Jeong
   • Uttam Ojha
   • You Mie Lee

   Original Article 04 November 2022 Pages: 117 - 132

   

8. Targeting ARHGEF12 promotes neuroblastoma differentiation, MYCN degradation, and reduces tumorigenicity

   • Yi Yang
   • Siqi Wang
   • Yanxin Li

   Original Article 15 December 2022 Pages: 133 - 143

   

9. IDH2, a novel target of OGT, facilitates glucose uptake and cellular bioenergy production via NF-κB signaling to promote colorectal cancer progression

   • Xiaoli He
   • Nan Wu
   • Jing Wu

   Original Article 19 November 2022 Pages: 145 - 164

   

10. Correction to: IDH2, a novel target of OGT, facilitates glucose uptake and cellular bioenergy production via NF-κB signaling to promote colorectal cancer progression

    • Xiaoli He
    • Nan Wu
    • Jing Wu

    Correction 27 December 2022 Pages: 165 - 166

    

11. TNFR2 antagonistic antibody induces the death of tumor infiltrating CD4⁺Foxp3⁺ regulatory T cells

    • Tianzhen He
    • Yibo Chen
    • Xin Chen

    Original Article 12 November 2022 Pages: 167 - 177

    

12. Kavain ablates the radio-resistance of IDH-wildtype glioblastoma by targeting LITAF/NF-κB pathway

    • Jianzhong Yu
    • Jun Shi
    • Xiongwei Wang

    Original Article 05 December 2022 Pages: 179 - 193

    

13. PKMYT1 inhibits lung adenocarcinoma progression by abrogating AKT1 activity

    • Shuang Wang
    • Ximeng Liu
    • Xu Li

    Original Article 09 November 2022 Pages: 195 - 209

    

14. Single cell profiling of γδ hepatosplenic T-cell lymphoma unravels tumor cell heterogeneity associated with disease progression

    • Wei Song
    • Haixi Zhang
    • Ruoyu Zhang

    Original Article Open access 22 November 2022 Pages: 211 - 226

    

15. PD-1-CD28 fusion protein strengthens mesothelin-specific TRuC T cells in preclinical solid tumor models

    • Stefanie Lesch
    • Alessia Nottebrock
    • Sebastian Kobold

    Short Communication Open access 21 November 2022 Pages: 227 - 235

    

16. Retraction Note: The POU2F1/miR-4490/USP22 axis regulates cell proliferation and metastasis in gastric cancer

    • Yizhi Xiao
    • Side Liu
    • Jide Wang

    Retraction Note Open access 29 December 2022 Pages: 237 - 237